ALAS2

Across TCGA pan-cancer cohorts, ALAS2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ALAS2 data layer compared with 19 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ALAS2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ALAS2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUAD, UCEC, and STAD are the cancer types where ALAS2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.380	0.820	<.001	35	view →
UCEC	DFS	Median	All	0.953	0.617	.006	16	view →
STAD	OS	Median	IV	0.001	0.544	<.001	12	view →
PAAD	OS	Median	All	0.132	0.640	.018	6	view →
BRCA	OS	Median	II,III,IV	0.801	0.958	.013	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ALAS2–LUAD (DFS)

Open the LUAD breakdown →